1. Updates in Lymphoma From Recent Congresses

2. Therapeutic Targets in CLL

3. Venetoclax in Patients With 17p Deletion

4. Venetoclax in Patients With 17p Deletion (cont)

5. Bendamustine Plus Obinutuzumab

6. Ibrutinib Plus Ublituximab

7. Updates in Lymphoma From Recent Congresses

8. EZH2 Inhibitor Tazemetostat

9. EZH2 Inhibitor Tazemetostat (cont)

10. Gene Expression Profiling in the Prediction of Disease Progression

11. Causes of Death in FL

12. Causes of Death in FL (cont)

13. FL Transformation

14. Cumulative Incidence by Rituximab Use (n = 6340)

15. Pembrolizumab Plus Rituximab

16. Pembrolizumab Plus Rituximab: Results

17. Lenalidomide Plus Rituximab

18. Lenalidomide Plus Rituximab (cont)

19. Updates in Lymphoma From Recent Congresses

20. The SCHOLAR-1 Study

21. CAR T-Cell Therapy: CTL019

22. CAR T-Cell Therapy: ZUMA-1 Trial of KTE-C19

23. Clinical Conclusions

24. Pembrolizumab For Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma

25. Updates in Lymphoma From Recent Congresses

26. The BRIGHT Trial: 5-Year Follow-Up

27. The BRIGHT Trial: 5-Year Follow-Up (cont)

28. Single-Agent Lenalidomide in Relapsed or Refractory MCL

29. Ibrutinib vs Temsirolimus

30. Combining Ibrutinib With Venetoclax

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)